Trial Profile

A retrospective cohort study to determine data for Durvalumab consolidation treatment initiation delays and reasons in patients with unresectable non-small cell lung cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Jul 2022 New trial record
07 Jun 2022 Results assessing treatment interruptions and discontinuations among patients with stage III unresectable non small cell lung cancer treated with durvalumab at the Veterans Health Administration, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
07 Jun 2022 Results (n=924)assessing racial disparities in the clinical use of durvalumab for patients with stage III unresectable non small lung cancer, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com